| Literature DB >> 28428042 |
Viharika Bobba1, Vishal Nanavaty2, Nethrie D Idippily1, Anran Zhao1, Bibo Li3, Bin Su4.
Abstract
African trypanosomiasis is still a threat to human health due to the severe side-effects of current drugs. We identified selective tubulin inhibitors that showed the promise to the treatment of this disease, which was based on the tubulin protein structural difference between mammalian and trypanosome cells. Further lead optimization was performed in the current study to improve the efficiency of the drug candidates. We used Trypanosoma brucei brucei cells as the parasite model, and human normal kidney cells and mouse macrophage cells as the host model to evaluate the compounds. One new analog showed great potency with an IC50 of 70nM to inhibit the growth of trypanosome cells and did not affect the viability of mammalian cells. Western blot analyses reveal that the compound decreased tubulin polymerization in T. brucei cells. A detailed structure activity relationship (SAR) was summarized that will be used to guide future lead optimization. Published by Elsevier Ltd.Entities:
Keywords: Drug development; Selective index; Trypanosomiasis; Tubulin inhibitor
Mesh:
Substances:
Year: 2017 PMID: 28428042 PMCID: PMC5509440 DOI: 10.1016/j.bmc.2017.04.009
Source DB: PubMed Journal: Bioorg Med Chem ISSN: 0968-0896 Impact factor: 3.641